28148284|t|Rasagiline - induced severe recurrent hypoglycemia in a young woman without diabetes: a case report
28148284|a|We report a case of a patient with recurrent severe hypoglycemia after initiating the drug rasagiline (Azilect) for Parkinson disease. A 25- year -old Emirati woman who had been diagnosed with Parkinson disease due to a genetic mutation since the age of 18 years presented to our hospital. She had been treated with a rotigotine patch 2 mg per day along with carbidopa + levodopa + entacapone 25 mg/100 mg/200 mg (Stalevo) over these years. Recently, her Stalevo had been changed to rasagiline (a monoamine oxidase B inhibitor). Soon after this change, she started experiencing recurrent documented severe hypoglycemia requiring hospitalization. Her hypoglycemic symptoms completely disappeared after 5-7 days of drug withdrawal. Despite detailed evaluation, no other causal relationship was documented except for rasagiline. To the best of our knowledge, this case report documents an unknown association between rasagiline and hypoglycemia.
28148284	0	10	Rasagiline	T109,T121	C0525678
28148284	13	20	induced	T046	C0007994
28148284	21	50	severe recurrent hypoglycemia	T046	C0342316
28148284	56	61	young	T079	C0332239
28148284	62	67	woman	T098	C0043210
28148284	76	84	diabetes	T047	C0011847
28148284	88	99	case report	T170	C0085973
28148284	112	116	case	T169	C0868928
28148284	122	129	patient	T101	C0030705
28148284	135	164	recurrent severe hypoglycemia	T046	C0342316
28148284	186	201	drug rasagiline	T109,T121	C0525678
28148284	203	210	Azilect	T109,T121	C1712038
28148284	216	233	Parkinson disease	T047	C0030567
28148284	241	245	year	T079	C1510829
28148284	251	264	Emirati woman	T098	C0043210
28148284	278	287	diagnosed	T033	C0011900
28148284	293	310	Parkinson disease	T047	C0030567
28148284	320	336	genetic mutation	T045	C0026882
28148284	347	350	age	T032	C0001779
28148284	357	362	years	T079	C1510829
28148284	380	388	hospital	T073,T093	C0019994
28148284	403	415	treated with	T061	C0332293
28148284	418	428	rotigotine	T109,T121	C1700683
28148284	440	447	per day	T079	C0439505
28148284	459	468	carbidopa	T109,T121	C0006982
28148284	471	479	levodopa	T116,T121,T123	C0023570
28148284	482	492	entacapone	T109,T121	C0165921
28148284	493	522	25 mg/100 mg/200 mg (Stalevo)	T200	C1329757
28148284	534	539	years	T079	C0439234
28148284	555	562	Stalevo	T200	C1329757
28148284	583	593	rasagiline	T109,T121	C0525678
28148284	597	626	monoamine oxidase B inhibitor	T121	C0595265
28148284	678	718	recurrent documented severe hypoglycemia	T046	C0342316
28148284	729	744	hospitalization	T058	C0019993
28148284	750	762	hypoglycemic	T047	C0020615
28148284	763	771	symptoms	T184	C1457887
28148284	805	809	days	T079	C0439228
28148284	813	828	drug withdrawal	T052	C2349954
28148284	847	857	evaluation	T058	C0220825
28148284	875	887	relationship	T080	C0439849
28148284	892	902	documented	T058	C1301725
28148284	914	924	rasagiline	T109,T121	C0525678
28148284	961	982	case report documents	T170	C0282574
28148284	1014	1024	rasagiline	T109,T121	C0525678
28148284	1029	1041	hypoglycemia	T047	C0020615